Cargando…
A randomised controlled trial of hearing and vision support in dementia: Protocol for a process evaluation in the SENSE-Cog trial
BACKGROUND: Optimising hearing and vision function may be important in improving a range of outcomes for people living with dementia (PwD) and their companions. The SENSE-Cog cross-national randomised controlled trial (RCT) is evaluating the effectiveness of a sensory intervention (SI) to improve qu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041097/ https://www.ncbi.nlm.nih.gov/pubmed/32093757 http://dx.doi.org/10.1186/s13063-020-4135-4 |
_version_ | 1783501104260055040 |
---|---|
author | Leroi, Iracema Armitage, Christopher J. Collin, Fidéline Frison, Eric Hann, Mark Hooper, Emma Reeves, David Simkin, Zoe Wolski, Lucas |
author_facet | Leroi, Iracema Armitage, Christopher J. Collin, Fidéline Frison, Eric Hann, Mark Hooper, Emma Reeves, David Simkin, Zoe Wolski, Lucas |
author_sort | Leroi, Iracema |
collection | PubMed |
description | BACKGROUND: Optimising hearing and vision function may be important in improving a range of outcomes for people living with dementia (PwD) and their companions. The SENSE-Cog cross-national randomised controlled trial (RCT) is evaluating the effectiveness of a sensory intervention (SI) to improve quality of life for PwD with concurrent hearing and/or vision impairment, in five European countries. To ascertain how or why the intervention will, or will not, achieve its outcomes, we have designed a process evaluation to explore potential discrepancies between expected and observed outcomes. This will also help us to understand how context may influence the outcomes. Here we describe the protocol for this process evaluation, which is embedded within the RCT. METHODS/DESIGN: We will use a mixed methods approach with a theoretical framework derived from the UK Medical Research Council’s’ guidance on process evaluations. It will include the following: (1) evaluating how key aspects of the intervention will be delivered, which will be important to scale the intervention in real world populations; (2) characterising the contextual issues, which may shape the delivery and the impact of the intervention in different countries; and (3) investigating possible causal mechanisms through analyses of potential moderators and mediators. To avoid bias, we will analyse the process data before the analysis of the main effectiveness outcomes. DISCUSSION: This evaluation will provide insight into how the complex SENSE-Cog SI will be tailored, enacted and received across the different European contexts, all of which have unique health and social care economies. The findings will provide insight into the causal mechanisms effecting change, and will determine whether we should implement the intervention, if effective, on a wider scale for PwD and concurrent sensory impairment. TRIAL REGISTRATION: ISRCTN, ISRCTN17056211. Registered on 19 February 2018. |
format | Online Article Text |
id | pubmed-7041097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70410972020-03-02 A randomised controlled trial of hearing and vision support in dementia: Protocol for a process evaluation in the SENSE-Cog trial Leroi, Iracema Armitage, Christopher J. Collin, Fidéline Frison, Eric Hann, Mark Hooper, Emma Reeves, David Simkin, Zoe Wolski, Lucas Trials Study Protocol BACKGROUND: Optimising hearing and vision function may be important in improving a range of outcomes for people living with dementia (PwD) and their companions. The SENSE-Cog cross-national randomised controlled trial (RCT) is evaluating the effectiveness of a sensory intervention (SI) to improve quality of life for PwD with concurrent hearing and/or vision impairment, in five European countries. To ascertain how or why the intervention will, or will not, achieve its outcomes, we have designed a process evaluation to explore potential discrepancies between expected and observed outcomes. This will also help us to understand how context may influence the outcomes. Here we describe the protocol for this process evaluation, which is embedded within the RCT. METHODS/DESIGN: We will use a mixed methods approach with a theoretical framework derived from the UK Medical Research Council’s’ guidance on process evaluations. It will include the following: (1) evaluating how key aspects of the intervention will be delivered, which will be important to scale the intervention in real world populations; (2) characterising the contextual issues, which may shape the delivery and the impact of the intervention in different countries; and (3) investigating possible causal mechanisms through analyses of potential moderators and mediators. To avoid bias, we will analyse the process data before the analysis of the main effectiveness outcomes. DISCUSSION: This evaluation will provide insight into how the complex SENSE-Cog SI will be tailored, enacted and received across the different European contexts, all of which have unique health and social care economies. The findings will provide insight into the causal mechanisms effecting change, and will determine whether we should implement the intervention, if effective, on a wider scale for PwD and concurrent sensory impairment. TRIAL REGISTRATION: ISRCTN, ISRCTN17056211. Registered on 19 February 2018. BioMed Central 2020-02-24 /pmc/articles/PMC7041097/ /pubmed/32093757 http://dx.doi.org/10.1186/s13063-020-4135-4 Text en © The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Leroi, Iracema Armitage, Christopher J. Collin, Fidéline Frison, Eric Hann, Mark Hooper, Emma Reeves, David Simkin, Zoe Wolski, Lucas A randomised controlled trial of hearing and vision support in dementia: Protocol for a process evaluation in the SENSE-Cog trial |
title | A randomised controlled trial of hearing and vision support in dementia: Protocol for a process evaluation in the SENSE-Cog trial |
title_full | A randomised controlled trial of hearing and vision support in dementia: Protocol for a process evaluation in the SENSE-Cog trial |
title_fullStr | A randomised controlled trial of hearing and vision support in dementia: Protocol for a process evaluation in the SENSE-Cog trial |
title_full_unstemmed | A randomised controlled trial of hearing and vision support in dementia: Protocol for a process evaluation in the SENSE-Cog trial |
title_short | A randomised controlled trial of hearing and vision support in dementia: Protocol for a process evaluation in the SENSE-Cog trial |
title_sort | randomised controlled trial of hearing and vision support in dementia: protocol for a process evaluation in the sense-cog trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041097/ https://www.ncbi.nlm.nih.gov/pubmed/32093757 http://dx.doi.org/10.1186/s13063-020-4135-4 |
work_keys_str_mv | AT leroiiracema arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT armitagechristopherj arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT collinfideline arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT frisoneric arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT hannmark arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT hooperemma arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT reevesdavid arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT simkinzoe arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT wolskilucas arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT arandomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT leroiiracema randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT armitagechristopherj randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT collinfideline randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT frisoneric randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT hannmark randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT hooperemma randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT reevesdavid randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT simkinzoe randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT wolskilucas randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial AT randomisedcontrolledtrialofhearingandvisionsupportindementiaprotocolforaprocessevaluationinthesensecogtrial |